Second-trimester cancer antigen 125 and Down's syndrome.
This study explores if assay of cancer antigen 125 (CA 125) in maternal serum might aid the detection of Down's syndrome in the second trimester of pregnancy. CA 125 levels were determined retrospectively in stored maternal serum samples from ten Down's syndrome pregnancies and 78 controls matched for gestational and maternal age. In addition, second-trimester amniotic fluid samples from nine Down's syndrome and 109 unaffected pregnancies were analysed for CA 125. Maternal serum CA 125 values for Down's syndrome pregnancies were lower, with the median being 0.72 multiples of the unaffected population median. The medians for affected and unaffected pregnancies did not differ significantly and there was a considerable overlap in the range of values of cases and controls. The distribution of amniotic fluid CA 125 levels for Down's syndrome pregnancies resembled that for controls. From our present results, we could not find an association between Down's syndrome and second-trimester maternal serum or amniotic fluid CA 125 levels.
Van Blerk
M
M
Centre for Reproductive Medicine, University Hospital, Brussels, Belgium.
Smitz
J
J
De Catte
L
L
Kumps
C
C
Van der Elst
J
J
Van Steirteghem
A C
AC
D000649:Amniocentesis; D000653:Amniotic Fluid / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D004314:Down Syndrome / Q000175:diagnosis*; D005260:Female; D006801:Humans; D011247:Pregnancy / Q000097:blood*; D011262:Pregnancy Trimester, Second; D012189:Retrospective Studies
D015295:Antigens, Tumor-Associated, Carbohydrate